Preclinical studies suggest that CBG may share many beneficial characteristics with CBD. Both CBG and CBD are non-intoxicating cannabinoids that potentially boast antioxidative, neuroprotective, and analgesic properties. When paired together, CBD and CBG may offer powerful anti-inflammatory benefits to treat neuroinflammation.
CBG stands for cannabigerol. Cannabigerol is one of more than 120 cannabinoids found in cannabis, and was first isolated in 1964.
Research into CBG is still at a preclinical stage, but the studies that are available suggest that it holds considerable therapeutic promise. CBG’s analgesic properties may surpass those of THC without the intoxicating hit. There’s also evidence to suggest CBG may offer anticancer, antidepressant, and antibacterial qualities.
Cannabigerolic acid (CBGA) is the chemical precursor to all of the well-known cannabinoids. As the cannabis plant matures and grows, enzymes convert CBGA into the three primary cannabinoid acids: tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), and cannabichromenic acid (CBCA).
Through decarboxylation, CBGA becomes CBG, enabling the cannabinoid to interact with the body’s cannabinoid receptors. Research suggests that CBG has a partial affinity for both the CB1 and CB2 receptors. CBG may also stimulate receptors that influence pain, inflammation, and heat sensitivity.
Disclaimer: This article does not provide medical advice. It is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment.